



Correction to: Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation


Yoriko Yamashita-Kashima¹ · Sei Shu¹ · Masahiro Osada¹ · Takaaki Fujimura¹ · Shigeki Yoshiura¹ · Naoki Harada¹ · Yasushi Yoshimura¹

Published online: 18 December 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to:
Cancer Chemotherapy and Pharmacology
(2020) 86:641–654
<https://doi.org/10.1007/s00280-020-04138-5>

In the original publication of the article, the author has found 2 errors as below:

1. Introduction: SLC46A2 has been changed to SLC46A3.
2. Figure 4c: the positions of the arrows were shifted up, the corrected figure is given below:



Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00280-020-04138-5>.

✉ Naoki Harada
haradanok@chugai-pharm.co.jp

¹ Product Research Department, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan